Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas

American Journal of Surgical Pathology

Volumn 22, Issue 10, 1998, Pages 1203-1214

  Ordóñez, Nelson G ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

44 3A6; Ber EP4; CA 125; CA19 9; Calretinin; CD15; Epithelial membrane antigen; HBME 1; Immunohistochemistry; Keratin; Mesothelioma; Ovary; Peritoneum; Placental alkaline phosphatase ; S 100 protein; Serous carcinoma; Thrombomodulin; Vimentin

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; KERATIN; PROTEIN S 100; THROMBOMODULIN; TUMOR MARKER; VIMENTIN;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PERITONEUM MESOTHELIOMA; PERITONEUM METASTASIS;

CYSTADENOCARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MESOTHELIOMA; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 19244379703     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199810000-00005     Document Type: Article

References (85)

1. Andressen C, Blumcke I, Celio MR. Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res 1993;271:181-208.
2. Ascoli V, Scalzo CC, Taccogna S, Nardi F. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med 1995;119:1136-40.
3. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 1996; 29:209-15.
4. Attanoos RL, Goddard H, Thomas ND, Jasani B, Gibbs AR. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Histopathology 1995;27:361-6.
5. Bateman AC, Al-Talib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997;30:49-56.
6. Beverley PCL, Souhami RL, Bobrow L. Results of the central data analysis. Lung Cancer 1988;4:15-36.
7. Bollinger DJ, Wick MR, Dehner LP, Mills SE, Swanson PE, Clarke RE. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma: A histochemical and immunohistochemical comparison. Am J Surg Pathol 1989;13:659-70.
8. Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12-9.
9. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24:347-54.
10. Chenard-Neu MP, Bellocq JP, Maier A, Batzenschlager A. Mésothéliomes malins de la plévre. Analyse de leurs aspects immunohistochemiques. Ann Pathol 1990;10:20-7.
11. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997;31: 140-3.
12. Collins CL. Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-33.
13. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. APMIS 1994;102:255-64.
14. Delahaye M, Hoogsteden HC, van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 1991;165:137-43.
15. De Leij L, Broers J, Ramaekers F, Berendsen H, Wagenaar SJSC. Monoclonal antibodies in clinical and experimental pathology of lung cancer. In: Ruiter DJ, Fleuren GJ, Warnaar SO, eds. Application of Monoclonal Antibodies in Tumor Pathology. Dordrecht: Martinus Nijhoff; 1987;191-210.
16. De Leij L, Helrich W, Stein R, Mattes MJ. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer Suppl 1994;8:60-3.
17. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-46.
18. Edwards C, Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed and paraffin wax embedded material. J Clin Pathol 1995;48:626-30.
19. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-6.
20. Fox H. Primary neoplasia of the female peritoneum. Histopathology 1993;23:103-10.
21. Frisman DM, McCarthy WF, Schleiff P, Buckner SB, Nocito JD Jr, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993;6:179-84.
22. Gaffey MJ, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992;16: 593-9.
23. Gitsch G, Tabery U, Feigl W, Breitenecker G. The differential diagnosis of primary peritoneal papillary tumors. Arch Gynecol Obstet 1992;251:139-44.
24. Gogate N, Deshmukh S. Immunohistochemical localisation of carcinoembryonic antigen (CEA) in malignant epithelial ovarian tumours using monoclonal antibodies. Indian J Pathol Microbiol 1995;38:199-201.
25. Grove A, Paulsen SM, Gregersen M. The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma. Pathol Res Pract 1994;190:1044-55.
26. Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
27. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986; 46:850-7.
28. Johnston WW. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. Acta Cytol 1987;31:537-56.
29. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J. Use of monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Res 1985;45:1894-900.
30. Jothy S, Brazinsky SA, Chin-A-Loy M, Haggarty A, Krantz MJ, Cheung M, Fuks A. Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity. Lab Invest 1986;54:108-17.
31. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol 1997;50:859-62.
32. Khoury N, Raju U, Crissman JD, Zarbo RJ, Greenawald KA. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. Hum Pathol 1990;21:811-9.
33. Kuenen-Boumeester V, van Loenen P, de Bruijn EMCA, Henzen-Logmans SC. Quality control of immunocytochemical staining of effusions using a standardized method of cell processing. Acta Cytol 1996;40:475-9.
34. Kuhlmann L, Berghäuser K-H, Schäffer R. Distinction of mesothelioma from carcinoma in pleural effusions: an immunocytochemical study on routinely processed cytoblock preparations. Pathol Res Pract 1991;187:467-71.
35. Latza U, Niedobitek G, Schwarting R, Nekarda R, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990;43:213-9.
36. Lee I, Radosevich JA, Chejfec G, Ma YX, Warren WH, Rosen ST, Gould VE. Malignant mesotheliomas: improved differential diagnosis from lung adenocarcinomas using monoclonal antibody 44-3A6 and 624A12. Am J Pathol 1986;123:497-507.
37. Leong AS-Y, Vernon-Roberts E. The immunohistochemistry of malignant mesothelioma. Pathol Annu 1994;29(part 2):157-79.
38. Magnani JL, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982;257:14365-9.
39. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489-92.
40. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994;10:130-4.
41. Makovitzky J. The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma: an immunohistochemical study. Virchows Arch B Cell Pathol 1986;51:535-44.
42. Maruyama I, Bell C, Majerus P. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblasts of human placenta. J Cell Biol 1985;101: 363-71.
43. McCaughey WT, Colby TV, Battifora H, et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. Mod Pathol 1991;4:342-53.
44. Miettinen M, Kovatich AJ. HBME-1 - a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumors. Appl Immunohistochem 1995;3: 115-22.
45. Miller K, Auld J, Jessup E, Rhodes A, Ashton-Key M. Antigen unmasking in formalin-fixed routinely processed paraffin wax-embedded sections by pressure cooking: a comparison with microwave oven heating and traditional methods. Adv Anatomic Pathol 1995;2:60-4.
46. Moch H, Oberholzer H, Dalquen N, Wegmann W, Gudat F. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: immunohistochemical findings. Virchows Arch Pathol Anat Histopathol 1993;423:19-27.
47. Moll R, Dhouailly D, Sun T-T. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Arch B Cell Pathol 1989;58:129-45.
48. Motoyama T, Watanabe T, Okazaki E, Tanaka N, Watanabe H. Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens. Acta Cytol 1995;39:164-70.
49. Neunteuffel W, Breitenecker G. Tissue expression of CA125 in benign and malignant lesions of the ovary and fallopian tube: a comparison with CA19-9 and CEA. Gynecol Oncol 1989;32:297-302.
50. Nouwen EJ, Hendrix PG, Dauwe S, Eerdekens MW, DeBroe ME. Tumor markers in the human ovary and its neoplasms: a comparative immunohistochemical study. Am J Pathol 1987;126:230-42.
51. O'Hara CJ, Corson JM, Pinkus GS, Stahel RA. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 1990;136:421-8.
52. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989;13:276-91.
53. Ordóñez NG. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. A comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-408.
54. Ordóñez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol 1998;109:85-9.
55. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998;29:166-9.
56. Ordóñez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology 1997;31:25-30.
57. Ordóñez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol 1987;26:1-10.
58. Ordóñez NG, Mackay B. The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anatomic Pathol 1996;3: 273-93.
59. Oshio G, Yamaki K, Imamura T, et al. Distribution of the carbohydrate antigens. DU-PAN-2 and CA19-9, in tumors of the lung. Tumori 1995;81:67-73.
60. Radosevich JA, Ma Y, Lee I, Salwen H, Gould VE, Rosen ST. Monoclonal antibody 44-3A6 as a probe for a novel antigen found in human lung carcinomas with glandular differentiation. Cancer Res 1985;45:5808-12.
61. Raife TJ, Lager DJ, Madison KC, et al. Thrombomodulin expression by human keratinocytes: induction of cofactor activity during epidermal differentiation. J Clin Invest 1994;93:1846-51.
62. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reeevaluation following heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-19.
63. Rothacker D, Möbius G. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. Int J Gynecol Pathol 1995;14:310-8.
64. Ruitenbeek T, Gouw ASH, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994; 118:265-9.
65. Savera AT, Raju U, Linden MD. Mesothelioma vs. adenocarcinoma: diagnostic utility of HBME-1. Lab Invest 1996;74:162A. Abstract.
66. Schwaller B, Buchwald P, Blumcke I, Celio MR, Hunziker W. Characterization of a polyclonal antiserum against the purified human recombinant calcium binding protein calretinin. Cell Calcium 1993;14:639-18.
67. Sheahan K, O'Brien MJ, Burke B, Dervan PA, O'Keane JC, Gottlieb LS, Zamcheck N. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol 1990;94:157-64.
68. Sheibani K, Shin SS, Kezirian J, Weiss LM. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991;15:779-84.
69. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 1994; 11:237-45.
70. Silcocks PB, Herbert A, Wright DH. Evaluation of PAS-diastase and carcinoembryonic antigen staining in the differential diagnosis of malignant mesothelioma and papillary serous carcinoma of the ovary. J Pathol 1986;149:133-41.
71. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 1997;10:716-9.
72. Souhami RL, Beverley PCL, Bobrow LG. Antigens of small-cell lung cancer. First International Workshop. Lancet 1987;2:325-6.
73. Spagnolo D, Whitaker D, Carrello S, Radosevich JA, Rosen ST, Gould VE. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma. Am J Clin Pathol 1991;95:322-9.
74. Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986;122:252-60.
75. Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986; 76:995-1006.
76. Truong LD, Maccato ML, Awalt H, Cagle PT, Schwartz MR, Kaplan AL. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol 1990;21:99-110.
77. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol 1988;133:30-8.
78. White PF, Merino MJ, Barwick KW. Serous surface papillary carcinoma of the ovary. A clinical, pathologic, ultrastructural and immunohistochemical study of 11 cases. Pathol Annu 1985;20(part 1):403-18.
79. Wick MR, Loy T, Mills SE, Legier JF, Manifel JC. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990;21:759-66.
80. Wick MR, Mills SE, Dehner LP, Bollinger DJ, Fechner RE. Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol 1989;8:179-88.
81. Wick MR, Mills SE, Swanson PE. Expression of "myelomonocytic" antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990;94:18-26.
82. Wick MR, Swanson PE, Manivel JC. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum Pathol 1987;18:946-54.
83. Wilson JD, Merino MJ, Harris C, Kleiner DE. Mesothelioma vs. adenocarcinoma: does immunohistochemistry help? Lab Invest 1997;76:174A.
84. Wirth PR, Legier J, Wright GL Jr. Immunohistochemical evaluation of seven antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991;67:655-62.
85. Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women: a clinicopathologic and immunohistochemical study. Cancer 1995;76:429-36.